07:32 AM EDT, 06/03/2024 (MT Newswires) -- Blackstone (BX) is exploring the sale of Alinamin Pharmaceutical Co., a Japanese consumer healthcare firm previously owned by Takeda Pharmaceutical Co. for around 300 billion yen ($1.9 billion), Bloomberg reported on Monday, citing people familiar with the situation.

Interest in Alinamin has been expressed by investment firms such as CVC Capital Partners Plc, EQT AB, and MBK Partners, according to the report.

Additionally, an IPO remains a viable option, it added.

Blackstone, CVC Capital Partners Plc, EQT AB, and MBK Partners did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 121.03, Change: +0.53, Percent Change: +0.44